
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI Inc. is poised for significant financial growth, with expectations of revenue increasing at a compound annual growth rate (CAGR) of 69% or more from fiscal year 2026 through fiscal year 2030 following the commercial launch of its DeepView System. The company's licensing model is projected to generate recurring revenue with high margins, positioning Spectral AI for predictable and stable growth within the MedTech sector. Additionally, improvements in efficiency demonstrated in clinical studies further bolster confidence in the company's operational effectiveness and market potential.
Bears say
Spectral AI Inc. has lowered its fiscal year 2025 revenue guidance to approximately $18.5 million, reflecting a decline of about 37.6% year-over-year from a prior estimate of $21.5 million, primarily due to delays related to the BARDA contract and the impact of the government shutdown. The company anticipates further revenue declines in fiscal year 2026, although specific guidance has not been provided, indicating a pessimistic outlook for continued revenue growth. Additionally, extended clinical and regulatory development timelines may result in decreased BARDA-related revenue, contributing to the overall negative financial projection.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares